Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today that it has entered into a strategic global research collaboration and licensing ...

Rznomics will conduct early-stage research according to the jointly approved research plans, while Lilly will assume responsibility for further development and commercialization.

Rznomics Inc. scored a potential ₩1.9 trillion (US$1.35 billion) global license option agreement with Eli Lilly and Co. to codevelop a novel RNA editing gene therapy to treat hereditary hearing loss.

WEST CHESTER, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin ...

Anticancer drug utilizing Trans-splicing Ribozyme technology Second Fast Track Designation following brain cancer approval SEONGNAM, South Korea, Feb. 18, 2025 /PRNewswire/ -- Rznomics announced ...

Rznomics announced on the 14th that its anticancer drug, RZ-001, has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of Hepatocellular Carcinoma ...

Rznomics, Inc. announced to secure its expanded access program (EAP) from the United States Food and Drug Administration (FDA) for RZ-001, RNA editing gene therapy product for the treatment of ...

SK pharmteco, a global contract development, manufacturing, and analytical testing organization, and Rznomics Inc., a South Korea-based biopharmaceutical company, have signed a memorandum of ...